## **Customer Support and Ordering Information**



## Benefit from the most comprehensive range of scientifically developed programs.

- More than 700 Surveys and anatomic pathology education programs across 16 disciplines.
- Benchmark with more than 23,000 laboratories using CAP PT/EQA Surveys and anatomic education programs.
- 600 experts in laboratory medicine support CAP offerings.

### **Customer Support and Ordering Information**

| Customer Support                                      | 32 |
|---|----|
| Ordering Information, Forms, and Terms and Conditions |    |
| Permitting Information                                | 37 |
| Shipping Information                                  | 44 |

### **Customer Support**

Customer Contact Center Hours: Monday-Friday, 7:00 AM-5:30 PM CT

Extended Support Hours: Monday-Friday, 9:00 PM-5:00 AM CT (email correspondence only)

| Contact Information   |  |  |  |
|---|--|--|--|
| Call us to:  • Place or modify an order  • Update contact and/or demographic information (laboratory name, address, contact email address, telephone and fax numbers)  • Discuss special needs  • Initiate CAPTRAKer⁵ email | 800-323-4040, Option 1<br>+1-847-832-7000, Option 1 (for customers outside the US)                         |  |  |
| To contact the CAP via email  | Email contactcenter@cap.org  OR  Go to cap.org and select Contact & Support at the bottom of the homepage. |  |  |
| To submit orders or permits   | Email cdm@cap.org  |  |  |
| Laboratory Accident Hotline   | 800-443-3244<br>+1-847-470-2812 (for customers outside the US)   |  |  |

#### CAPTRAKer Email

The CAP's electronic proficiency testing (PT) kit—also referred to as external quality assessment (EQA)—shipment-tracking service offers these benefits to your laboratory:

- · Locate your PT kit in an instant.
- Receive CAPTRAKer emails notifying you of program shipments.
- Link to carrier tracking information through a CAPTRAKer email.

To initiate the receipt of CAPTRAKer emails, please forward your name, account number, and email address to contactcenter@cap.org.

#### e-LAB Solutions Suite

Use the CAP's online portal to manage your laboratory improvement programs. The portal provides helpful, convenient, and easy-to-use tools to:

- Access the CAP's web-based reporting solution, Performance Analytics Dashboard.
- Enter, review, and approve your PT results with interactive online forms.
- View and print copies of evaluations, participant summaries, kit instructions, and result forms.
- · Access your analyte scorecard, customized PT shipping calendar, and other analytical tools.
- View and update your CMS analyte reporting selections to ensure proper regulatory reporting.
- Manage your laboratory's online access and user permissions, as well as your individual profile.
- Manage your accreditation documents, including customized accreditation checklists and test menu/activity change forms.
- Enhance your automated reporting capabilities with e-LAB Solutions Connect (available in the US and Canada).
- Connect to CAP Learning tools, assessments, and modules.

This site contains a Users Guide that will guide you through the process of using e-LAB Solutions Suite. When you enroll/register for e-LAB Solutions Suite, your laboratory will receive important email notifications regarding PT events such as kit and evaluation availability.

#### **Program Certificates**

At the completion of the program year, each participating laboratory will receive a program certificate that recognizes that institution's participation in the CAP Surveys and Anatomic Pathology Education Programs. This certificate is an indication of your commitment to quality improvement for better patient care.

#### **Program Usage and Materials**

- All program materials are intended for PT use only.
- You may not transfer or incorporate PT samples, their progeny, unmodified derivatives, or modifications thereof into a program intended for sale or uses other than PT, quality assurance, or education.
- Upon disposal of PT samples, their progeny, reagents, disposable equipment, unmodified derivatives, or modifications thereof used in PT, you should autoclave or incinerate and dispose of these materials as hazardous waste.
- All directions concerning use of the program materials are intended as guidance only.
- No license is either granted or implied by the sale of any program.
- The CAP contracts with vendors in producing the materials for its PT programs.
- The CAP follows PT manufacturer directions in determining the packaging, transport, and shipping conditions of all materials. These requirements may differ from the in-laboratory storage specifications indicated in the kit instructions that accompany your PT.
- Upon delivery of your PT, follow the kit instructions immediately and conduct testing as soon as possible.

#### **Laboratory Accident Hotline**

#### 800-443-3244

#### +1-847-470-2812 (for customers outside the US)

Accidental exposures while processing specimens from the CAP, including cuts and contamination of mucous membranes or non-intact skin, should be reported to the CAP hotline for evaluation and questions regarding prophylaxis. Please provide the identification number of the relevant specimen.

#### **Biohazard Information/Warning Statements**

- The Centers for Disease Control and Prevention (CDC) has classified all bacterial and viral strains used in PT challenges as not greater than a Biosafety Level 2. A full description of Biosafety Level 2 handling requirements as defined by the CDC Office of Health and Safety in Biosafety in Microbiological and Biomedical Laboratories is provided at cdc.gov/labs/BMBL.html.
- All programs include a biohazard warning statement appropriate for handling of the material.
- Programs that do not include etiologic agents are still expected to be handled in keeping with CDC universal precautions and OSHA bloodborne pathogen rules.
- The CAP's Safety Data Sheets (SDS/MSDS) are available on cap.org (Laboratory Improvement > Catalog and Ordering Information).

#### **Governing Law**

• All CAP transactions are governed by Illinois state law. Unless otherwise stated, US Commercial Code prevails.

#### **CMS Reporting**

- The CAP must submit PT results to the CMS for all laboratories providing a CLIA identification number.
- Your reporting preferences are outlined on the CMS Analyte Reporting Selections document, which is available online in e-LAB Solutions Suite.
- If a laboratory does not notify the CAP in advance that they have discontinued testing of a regulated analyte, a score of zero will be given.
- To avoid any penalties and ensure appropriate reporting in the future, you must note analytes listed on this report for which you do not perform testing.

#### PT Referral

#### Please share this information with anyone who performs and/or manages PT specimens.

PT referral has come under greater scrutiny from inspectors for the CMS. The CAP's PT Program reminds participants that per CLIA '88, a laboratory must test the PT specimens it receives in the same manner as it tests patient specimens—specimens must be tested with the laboratory's *regular workload*, using the laboratory's *routine methods*, and the *same number of times* it routinely tests patient specimens. However, laboratories *must not communicate results*, *share PT specimens*, *or refer PT specimens* to a laboratory with a *different CLIA number* for tests not on the laboratory's menu even if the referral for testing is routinely performed for patient specimens.

## Ordering Information, Forms, and Terms and Conditions

#### **Current Customers (placing your renewal order)**

- Programs ordered as of August 1, 2024, are prepopulated on your order renewal form.
- Review all prepopulated PT ordering information including program enrollment, kit quantity, and demographic data.
- Refer to the Surveys catalog for program changes and discontinued or new programs.
- · You can also see a list of programs in your PT Shipping Calendar at cap.org.
- · Renew online:
  - o Visit cap.org and select Shop at the top of the homepage. Log in and go to "I'm making purchases for" to select your laboratory.
  - o Review, modify, and submit the prepopulated quote found under the "Quotes" link.
  - o Note: To begin ordering on behalf of your organization, you will need to have ordering privileges granted by your Site Administrator.
- Use the prepopulated order forms:
  - o Print clearly and follow all instructions for adding and canceling programs. Legible printing will help ensure the accuracy of your order.
  - o Review ALL pages of your renewal order form.
  - o Provide clear and complete shipping address, contact name, telephone number, and email address information on your order form. The CAP cannot accept PO boxes for shipments.
  - o Complete form with payment information and RETURN ALL PAGES by email to cdm@cap.org.
- Upon receipt of the order, an email acknowledgment will be sent to the shipping contact listed.
- Once processed, an order confirmation will be emailed to the shipping contact. Order changes can be made at that time.

#### New Customers (placing your initial order)

- New customers may browse the online store, but must email completed order forms to cdm@cap.org to be assigned a CAP
  account number.
- Visit cap.org and go to the Laboratory Improvement > Catalog and Ordering Information section to access a CAP order form.
- Complete ALL pages of the order form, including payment information. Provide clear and complete shipping address, contact name, telephone number, and email address information.
- The CAP cannot accept PO boxes for shipments. If you cannot have your order shipped to a street address, contact the CAP Contact Center.
- Return ALL pages of the order form and payment information to cdm@cap.org.
- Upon receipt of the order, an email acknowledgement will be sent to the shipping contact listed.
- Once processed, an order confirmation will be emailed to the shipping contact. Order changes can be made at that time.

#### **All Customers**

- If you require additional documentation regarding the CAP's status in order to place orders or to receive shipments, please contact the CAP Customer Data Management (CDM) department at cdm@cap.org. Examples of available documentation include US IRS Form 6166 Certificate of Residency, Articles of Incorporation, and the CAP's tax status.
- Material and Safety Data Sheets are available at cap.org (Laboratory Improvement > Catalog and Ordering Information).

#### **Order Deadline**

- Order by December 1, 2024, to ensure full participation.
- Order early. Programs have limited quantities.
- Orders received after December 1 will be processed by date of receipt and prorated per program availability.

#### **Order Additions and Cancellations**

- The CAP will make every effort to accommodate orders received after December 1. Orders are dependent on the shipping schedule, specimen availability, and specimen stability.
- Due to vendor commitments, the CAP must receive cancellations no later than **six weeks** prior to the published ship date to give credit for canceled programs.
- Program shipping fee refund requests will not be honored if received within the six week period prior to the first scheduled shipment date.
- The CAP does not accept the physical return of PT/EQA programs. Participants are responsible for all costs and expenses related to the return of anatomic pathology slide shipments to the CAP if the reason for such return is late program cancellation, refused shipment, or invalid ship-to address.
- Products received in unsuitable condition to perform testing for any reason may be rejected and discarded by the customer. The customer will receive, at its option, a full credit of the purchase price or the replacement of the products at no additional charge and with no additional cost of shipping.

#### Prelicensure/Reinstatement Service

- The CAP provides PT samples to laboratories that may need to perform prelicensure testing before beginning patient testing and/or reinstatement testing due to PT failures. Contact the CAP for cost and availability.
- PT samples with limited stability are not available for prelicensure/reinstatement testing.
- Reinstatement evaluations will be provided upon submission of results to the CAP.

#### **CAP and CLIA Numbers**

- Please have your CAP number available when placing orders. For new CAP customers, a CAP number will be assigned to the laboratory and will appear on your order confirmation.
- For all customers subject to CLIA: Confirm or provide the laboratory's CLIA identification number, which is assigned by the Centers for Medicare & Medicaid Services (CMS) and can be obtained from your laboratory director. Contact your CMS Regional Office if you do not have a CLIA identification number.
- Orders may be submitted pending assignment of your CLIA number. Forward the number to the CAP once assigned.

#### Prices/Estimated Costs for Laboratories Outside the US

- Prices exclude taxes, duties, brokerage fees, disbursement fees, and other applicable shipping and customs charges. These fees are the responsibility of the importer. All prices are subject to change without notice.
- The CAP reserves the right to change the published prices and ship dates.
- Estimated Costs: Contact the CAP if your institution requires an estimated cost (provided as a pro-forma invoice) prior to submitting payment. Upon receipt of the pro-forma invoice, submit the completed order form, including payment method, to the CAP for processing of your order.
  - o A pro-forma invoice can be requested by including the request when submitting your order forms, contacting the CAP, or via the online store.

#### **Payment**

Complete the Payment Information section of the order form. **To avoid delay in the processing of your order,** you must use one of the five following methods of payment:

- Checks: Make payable to the College of American Pathologists in US dollars and indicate the check number on the form.
- Credit card (VISA, Mastercard, and American Express): For increased customer data safety, please visit estore.cap.org to place your order. To pay with a credit card, please call the CAP directly at 800-323-4040 or +1-847-832-7000, Option 1.
- Purchase Order: A purchase order indicates a future commitment to pay. Indicate the purchase order number on the order form. All orders for Canadian customers must be accompanied with a purchase order number. Customs brokers cannot facilitate clearance without a purchase order number for reference.

#### Payment continued on next page

#### Payment (continued)

- Letter of Authorization: If your institution does not use a purchase order system, a signed letter of authorization on your institution's letterhead is acceptable. Please include the payment method information (bank draft, wire transfer, etc) in your letter. Indicate this payment option selection on the order form and include a copy of the letter with your completed form.
- Wire Transfer Information
  - o Include all bank fees with your payment. The CAP is not responsible for bank fees incurred while remitting payment. Make arrangements with your financial institution to include all wire transfer fees charged by intermediary banks.
  - o Short payment due to deduction of intermediary bank fees will leave an open balance on your account. You are responsible to pay this balance in your next wire transfer to the CAP.
  - o Remit wire transfer payment to:
    - BMO Bank N.A., 320 S. Canal Street, Chicago, IL 60606
    - Phone: +1-312-461-2323
    - Account Name: College of American Pathologists
    - Account Number/Type: 2237337/Checking
    - Routing/Transit: 071000288
    - S.W.I.F.T.: HATRUS44
  - o Include the following information:
    - Customer name
    - CAP number
    - Account number
    - Invoice and/or order number

#### **Payment Terms and Conditions**

- For orders processed by October 31, 2024, payment terms are extended until December 1, 2024.
- After November 1, 2024, terms will be net 30 days from the invoice date.

#### **Tax Information**

- The CAP will calculate and add appropriate taxes for your locale to your invoice if your institution is subject to sales tax.
- · Include applicable taxes with your prepaid order.
- Enclose your tax-exempt certificate with your order form if your institution is not subject to sales tax or if you have not previously notified the CAP with any changes.
- The CAP federal tax identification number is 36-2118323.

#### **Export Compliance:**

The specimens and material and any related technology, including technical information supplied by the CAP or contained in documents (collectively "items"), are subject to export controls of the US government. The export controls may include—but are not limited to—those of the export administration regulations of the US Department of Commerce (the "EAR"), which may restrict or require licenses for the export or re-export of items from the United States and the import of any item. The CAP will not export or distribute any item to any restricted or embargoed country, or to any person or entity whose participation has been denied or restricted by the US government.

By submitting an order for any materials or services, you, the Buyer, acknowledge that you are following compliance with the international trade laws of the US and those of your country. You agree to cooperate fully with the CAP in any official or unofficial inspection related to applicable export or import laws or regulations. Further you shall indemnify and hold the CAP harmless from, or in connection with, any violation of US export laws by your employees, consultants, agents, or customers.

This catalog is governed by the contract terms found on the CAP website at cap.org/terms-and-conditions. In the event of any contradiction between this catalog and the website, the terms in this catalog shall prevail. The CAP shall not accept, or allow any order to be subjected to, any terms and conditions supplied by the customer.

## **Permitting Information**

#### What you need to know before your PT program is shipped:

#### **General Permit Requirement Information**

Many countries require additional import permits or other clearance documentation for customs clearance (regardless of dangerous goods status of a program).

- Work with your in-country distributor (if applicable) and local authorities to determine if any permits are required.
- As a recipient, you are responsible for obtaining any import permits/documents and forwarding these to the CAP upon request. Provide these same documents to your local carrier, importing agency, or customs brokerage service.
- · Programs with dangerous goods materials may require special permits and incur additional charges.
- Do not use the CAP Surveys catalog program descriptions for permit preparation and customs clearance documents. Program specifications may have changed after catalog publication and do not provide sufficient detail. Contact the CAP to obtain such information.
- Some new programs may not have permit requirements available at the time of publication. In the event a program is not listed, please contact your local importation agencies.
- You are responsible for monitoring permit expiration dates and submitting a new permit six weeks prior to the scheduled ship date. Check with your local governmental importation authorities or your local in-country distributor (if applicable), which may have longer lead time requirements and adjust your permit obligations accordingly.
- Program materials will not ship without required documentation.

Submit permits at the time of ordering with an expiration date of December 31, 2025, to cover all shipments. At a minimum, submit permits six weeks prior to the stated program ship date to ensure timely delivery.

#### **Additional Documentation**

If you require additional documentation regarding the CAP's status in order to place orders or to receive shipments, please contact the CAP Customer Data Management (CDM) department at cdm@cap.org. Examples of available documentation include US IRS Form 6166 Certificate of Residency, Articles of Incorporation, and the CAP's tax status.

Material and Safety Data Sheets are available at cap.org (Laboratory Improvement > Catalog and Ordering Information).

#### Contact your local customs agency for importation requirements.

|              | Programs Classified as l                    |
|--------------|---|
| Program Code | Program Name                                |
| BCS          | Blood Culture                               |
| BCS1         | Blood Culture, Staphylococcus aureus        |
| BDP, BDP5    | Bacterial Detection in Platelets            |
| BDPV5        | Bacterial Detection in Platelets, Rapid     |
| CAMP         | Campylobacter                               |
| CBT          | Cord Blood Testing                          |
| CRE          | Carbapenemase Detection                     |
| D            | Bacteriology                                |
| DEX          | Expanded Bacteriology                       |
| D1           | Group A Streptococcus Culture/<br>Molecular |
| D2           | Urine Culture                               |
| D3           | N. gonorrhoeae Culture                      |
| D8           | Group B Strep Detection                     |
| Е            | Mycobacteriology                            |
| E1           | Mycobacteriology—Limited                    |
| F            | Mycology                                    |
| F1           | Yeast                                       |
| F3           | Candida Culture                             |
| HC4          | Herpes Culture                              |

| N3373 Dangerous Goods |   |  |
|-----------------------|---|--|
| Program Code          | Program Name  |  |
| HC6, HC6X             | C. trachomatis and N. gonorrhoeae by NAA                        |  |
| HPS                   | Helicobacter pylori Antigen, Stool                              |  |
| IDN                   | Nucleic Acid Amplification, Organisms (without MTB)             |  |
| IDO                   | Nucleic Acid Amplification, Organisms                           |  |
| LPX                   | Laboratory Preparedness Exercise                                |  |
| MBT                   | Microbiology Bench Tools Competency                             |  |
| MC3                   | Urine Colony Count  |  |
| MC4                   | Urine Colony Count Combination                                  |  |
| MRS                   | Methicillin-Resistant Staphylococcus aureus Screen              |  |
| MRS5                  | Methicillin-Resistant Staphylococcus aureus Screen, 5 Challenge |  |
| RMC                   | Routine Microbiology Combination                                |  |
| SCP                   | Stem Cell Processing  |  |
| VR1                   | Virology Culture  |  |
| VRE                   | Vancomycin-Resistant Enterococcus                               |  |
| VS                    | Vaginitis Screen Antigen Detection – BD<br>Affirm VP III        |  |

**WARNING:** The **Instrumentation (I) program** specimens may contain corrosive or toxic substances, environmental hazards, or irritants. This program ships under a UN3264 Class 9 Dangerous Goods Classification in Excepted Quantities with a specimen volume below the threshold requiring special packaging.

Note: CAP Viral Measures VM1-VM6X do not ship under a Dangerous Goods Classification; however, some countries may still require permits due to the nature of the material.

#### **Hawaiian Permits**

Import permits are required by the state of Hawaii. You may obtain an import permit by contacting the Plant Quarantine Branch of the State of Hawaii Department of Agriculture. Complete form PQ-7 to obtain an import permit or a letter of authorization.

|                 | Hawaiian Perr                               |                              |  |
|-----------------|---|------------------------------|--|
| Program<br>Code | Program Name                                | Documentation<br>Requirement |  |
| ВСМ             | Bacterial Blood Culture,<br>Molecular       | AR                           |  |
| BCS             | Blood Culture                               | NR                           |  |
| BCS1            | Blood Culture, S. aureus                    | NR                           |  |
| BDP,<br>BDP5    | Bacterial Detection in Platelets            | NR                           |  |
| BDPV5           | Bacterial Detection in Platelets,<br>Rapid  | NR                           |  |
| BOR             | B. pertussis/parapertussis,<br>Molecular    | AR                           |  |
| BP              | Blood Parasite                              | AR                           |  |
| BV              | Bacterial Vaginosis                         | AR                           |  |
| CAMP            | Campylobacter                               | NR                           |  |
| CBT             | Cord Blood Testing                          | NR                           |  |
| CDF2,<br>CDF5   | Clostridioides (Clostridium)<br>difficile   | AR                           |  |
| COV2            | SARS-CoV-2 Molecular                        | AR                           |  |
| COV2Q           | Q Quality Cross Check—SARS-<br>CoV-2 AR     |                              |  |
| COVAG           | SARS-CoV-2 Antigen                          | AR                           |  |
| COVAQ           | Quality Cross Check—SARS-<br>CoV-2 Antigen  | AR                           |  |
| CRE             | Carbapenamase Detention                     | NR                           |  |
| CRYP            | Cryptococcal Antigen Detection              | AR                           |  |
| CVAG            | SARS-CoV-2 Antigen, 5 Challenge             | AR                           |  |
| D               | Bacteriology                                | NR                           |  |
| D1              | Group A Streptococcus Culture/<br>Molecular | NR                           |  |
| D2              | Urine Culture P                             |                              |  |
| D3              | N. gonorrhoeae Culture                      | NR                           |  |
| D5              | Gram Stain                                  | AR                           |  |
| D6              | Rapid Group A Strep Antigen Detection  AR   |                              |  |
| D8              | Group B Strep Detection                     | NR                           |  |
| D9              | Rapid Strep Antigen Detection,<br>Waived    | AR                           |  |
| DEX             | Expanded Bacteriology                       | NR                           |  |

| t Require          | ements   |                              |
|--------------------|--|------------------------------|
| Program<br>Code    | Program Name   | Documentation<br>Requirement |
| Е                  | Mycobacteriology   | Р                            |
| E1                 | Mycobacteriology—Limited   | Р                            |
| F                  | Mycology and Aerobic<br>Actinomycetes                                | Р                            |
| F1                 | Yeast  | Р                            |
| F3                 | Candida Culture  | Р                            |
| FSM                | Fungal Smear   | AR                           |
| GIP, GIP5,<br>GIPN | Gastrointestinal Panel   | AR                           |
| НС3                | C. trachomatis Antigen Detection (EIA)                               | AR                           |
| HC4                | Herpes Simplex Virus, Culture  | NR                           |
| HC6,<br>HC6X       | C. trachomatis/N. gonorrhoeae by<br>Nucleic Acid Amplification (NAA) | NR                           |
| HC7                | C trachomatis/N gonorrhoege  |                              |
| HPS                | <i>H. pylori</i> Antigen, Stool                                      | NR                           |
| HPV                | Human Papillomavirus   | AR                           |
| ID1                | Nucleic Acid Amplification,<br>Viruses AR                            |                              |
| ID1T               | Nucleic Acid Amplification,<br>Viruses (JC and BK)                   | AR                           |
| ID2                | Nucleic Acid Amplification,<br>Respiratory                           | AR                           |
| ID3                | Nucleic Acid Amplification,<br>Respiratory Limited                   | AR                           |
| ID5                | HSV, VZV—Molecular   | AR                           |
| IDME               | Meningitis/Encephalitis Panel  | AR                           |
| IDM5               | Maningitie/Encaphalitie Panal 5                                      |                              |
| IDN                | NAA, Organisms (without MTB) NR                                      |                              |
| IDO                | Nucleic Acid Amplification, Organisms                                |                              |
| IDPN               | Infectious Disease, Pneumonia<br>Panel                               | AR                           |
| IDR                | Infectious Disease, Respiratory<br>Panel                             | AR                           |
| Continue           | d on next page   |                              |

#### **Permit Definitions**

AR = AR Letter: Hawaii Department of Agriculture letter for programs not specifically regulated but still requiring documentation for importing NR = NR Letter: Hawaii Department of Agriculture letter for programs considered to be low risk but still requiring documentation for importing P = Permit

|  | Hawaiia  | ın Permit R                  |  |
|--|--|------------------------------|--|
| Program<br>Code  | Program Name   | Documentation<br>Requirement |  |
| IND  | India Ink  | AR                           |  |
| JIP  | Joint Infection Panel                                    | AR                           |  |
| LBAS   | Legionella Antigen Detection                             | AR                           |  |
| LN38   | CMV Viral Load   | AR                           |  |
| LPX  | Laboratory Preparedness<br>Exercise                      | Р                            |  |
| MBT  | Micro Bench Tools Competency                             | NR                           |  |
| MC3  | Urine Colony Count                                       | NR                           |  |
| MC4  | Urine Colony Count Combination                           | NR                           |  |
| MGEN Mycoplasma genitalium, Molecular                        |  | AR                           |  |
| MPOX   | Mpox Molecular   | AR                           |  |
| MRS, Methicillin-Resistant MRS5 Staphylococcus aureus Screen |  | NR                           |  |
| MRS2M  | MRSA Screen, Molecular                                   | AR                           |  |
| MRS5M  | MRSA Screen, Molecular                                   | AR                           |  |
| MTBR   | MTBR Molecular MTB Detection and Resistance              |                              |  |
| MTR5   | MTR5 Molecular MTB Detection and Resistance, 5 Challenge |                              |  |
| MVP  | Molecular Vaginal Panel                                  | AR                           |  |
| NAT  | NAT Nucleic Acid Testing                                 |                              |  |
| Р  | Parasitology   | AR                           |  |
| Parasitology (Fecal Suspension, Immunoassay)                 |  | AR                           |  |
| P4   | Parasitology (Fecal Suspension, PVA, Immunoassay)        | AR                           |  |
| P5   | Parasitology (Gigrdig/Crypto                             |                              |  |

| quirements continued |   |                              |
|----------------------|---|------------------------------|
| Program<br>Code      | Program Name                                  | Documentation<br>Requirement |
| POC4                 | POC Strep Screen Competency                   | AR                           |
| POC8                 | Influenza A/B Antigen Detection<br>Competency | AR                           |
| RMC                  | Routine Microbiology<br>Combination           | NR                           |
| RML5                 | Rapid Malaria 5 Challenge                     | AR                           |
| SBAS                 | S. pneumoniae Antigen Detection               | AR                           |
| SCP                  | Stem Cell Processing                          | NR                           |
| SP                   | Stool Pathogens                               | AR                           |
| SP1                  | Norovirus                                     | AR                           |
| SPN                  | Stool Pathogen (without<br>Shiga Toxin)       | AR                           |
| ST                   | Shiga Toxin                                   | AR                           |
| STIM                 | Sexually Transmitted Infection                | AR                           |
| TVAG,<br>TVG5        | T. vaginalis, Molecular                       | AR                           |
| VBDM                 | Vector-Borne Disease—<br>Molecular            | AR                           |
| VR1                  | Virology Culture                              | NR                           |
| VR2                  | Virology Antigen Detection (DFA)              | AR                           |
| VR4                  | Virology Antigen Detection (Non-<br>DFA)      | AR                           |
| VRE                  | Vancomycin-Resistant<br>Enterococcus          | NR                           |
| VS                   | Vaginitis Screen Antigen<br>Detection         | NR                           |
| VS1                  | Vaginitis Screen, T. vaginalis                | AR                           |
| YBC                  | Yeast Blood Culture, Molecular                | AR                           |

#### **Permit Definitions**

AR = AR Letter: Hawaii Department of Agriculture letter for programs not specifically regulated but still requiring documentation for importing NR = NR Letter: Hawaii Department of Agriculture letter for programs considered to be low risk but still requiring documentation for importing P = Permit

#### **Canadian Permits**

Canadian regulations require permits to import animal, plant, and human pathogens. Permit applications should list the CAP program code and full program name. Do not list the Program Fulfillment Group (PFG). Do not list the mailing designation (A, B, C).

Recipients must obtain the appropriate permits for all infectious modules. Questions regarding importation requirements for Canada should be directed to the government agencies noted below.

- The Public Health Agency of Canada (PHAC). Contact licence.permis@phac-aspc.gc.ca.
- Canadian Food Inspection Agency (CFIA) permits may also be required. Contact permission@inspection.gc.ca.

|                 | Canadian I                                    | Permit Rec  | quirement                                      | S   |                              |                                 |
|-----------------|---|---|--|---|------------------------------|---------------------------------|
| Program<br>Code | Program Name                                  | PHAC<br>License:<br>HAR (RG2) &<br>HPTR (RG2) if<br>culturing | PHAC<br>License:<br>HPTR (RG2) if<br>culturing | CFIA OBCS<br>(aquatic-<br>animal HAA/<br>HAR) | CFIA<br>Compliance<br>Letter | CFIA COA<br>(plant PPA/<br>PPR) |
| BCS             | Blood Culture                                 | Х   |  |   |                              |                                 |
| BCS1            | Blood Culture, S. aureus                      | Х   |  |   |                              |                                 |
| BDP,<br>BDP5    | Bacterial Detection in Platelets              | X   |  | X   | Х                            |                                 |
| BDPV5           | Bacterial Detection in Platelets, Rapid       | Х   |  | Х   | X                            |                                 |
| CAMP            | Campylobacter                                 | Х   |  | Х   | Х                            |                                 |
| CBT             | Cord Blood Testing                            |   |  | X   | Х                            |                                 |
| COV2            | SARS-CoV-2, Molecular                         |   | X  |   |                              |                                 |
| COV2Q           | Quality Cross Check, SARS-CoV-2,<br>Molecular |   | X  |   |                              |                                 |
| COVM            | SARS-CoV-2 Molecular, 5 Challenge             |   | Χ  |   |                              |                                 |
| CRE             | Carbapenemase Detection                       | Х   |  | Х   | X                            |                                 |
| D               | Bacteriology                                  | Х   |  | Х   | Х                            |                                 |
| D1              | Group A Streptococcus Culture/Molecular       | Х   |  | Χ   | Х                            |                                 |
| D2              | Urine Culture                                 | Х   |  | X   | Х                            |                                 |
| D3              | N. gonorrhoeae Culture                        | Х   |  | Х   | Х                            |                                 |
| D8              | Group B Strep Detection                       | Х   |  | X   |                              |                                 |
| DEX             | Expanded Bacteriology                         | Х   |  | Х   | Х                            |                                 |
| Е               | Mycobacteriology                              | X   |  | Χ   | Χ                            |                                 |
| E1              | Mycobacteriology—Limited                      | Х   |  | Х   | Х                            |                                 |
| F               | Mycology and Aerobic Actinomycetes            | Х   |  | Х   | Х                            | Х                               |
| F1              | Yeast   | Х   |  | Х   | Х                            |                                 |
| F3              | Candida Culture                               | Х   |  | Х   | X                            |                                 |
| GIP5            | Gastrointestinal Panel, 5 Challenges          | Х   |  |   |                              |                                 |

#### Continued on next page

#### **Definitions**

HAA/HAR—Health of Animals Act and Health of Animals Regulations

HPTR—Human Pathogens and Toxins Regulations

PPA/PPR—Plant Protection Act and Plant Protection Regulations

OBCS—Office of Biohazard Containment and Safety

RG2—Risk Group 2

| Program<br>Code | Program Name   | PHAC<br>License:<br>HAR (RG2) &<br>HPTR (RG2) if<br>culturing | PHAC<br>License:<br>HPTR (RG2) if<br>culturing | CFIA OBCS<br>(aquatic-<br>animal HAA/<br>HAR) | CFIA<br>Compliance<br>Letter | CFIA COA<br>(plant PPA/<br>PPR) |
|-----------------|--|---|--|---|------------------------------|---------------------------------|
| GIPN            | Gastrointestinal Panel Global  | X   |  |   |                              |                                 |
| HC4             | Herpes Simplex Virus, Culture  | Х   |  |   |                              |                                 |
| HC6,<br>HC6X    | C. trachomatic/N. gonorrhoeae by Nucleic<br>Acid Amplification (NAA) |   | Х  |   |                              |                                 |
| HPS             | H. pylori Antigen, Stool   | Х   |  |   |                              |                                 |
| ID1             | Nucleic Acid Amplification, Viruses                                  |   | Х  |   |                              |                                 |
| ID2             | Nucleic Acid Amplification, Respiratory                              |   | Х  |   |                              |                                 |
| ID3             | Influenza A, Influenza B, and RSV by NAA                             |   | Х  |   |                              |                                 |
| IDME            | Meningitis/Encephalitis Panel  |   | Х  |   |                              |                                 |
| IDM5            | Meningitis/Encephalitis Panel, 5 Challenge                           |   | Х  |   |                              |                                 |
| IDO, IDN        | Nucleic Acid Amplification, Organisms                                | Х   |  | Х   | Х                            |                                 |
| IDPN            | Infectious Disease, Pneumonia  |   | Х  |   |                              |                                 |
| IDR             | Infectious Disease, Respiratory Panel                                |   | Х  |   |                              |                                 |
| MBT             | Micro Bench Tools Competency   | Х   |  | Х   | Х                            |                                 |
| MC3             | Urine Colony Count   | Х   |  | Χ   | Х                            |                                 |
| MC4             | Urine Colony Count Combination                                       | Х   |  | Х   | Х                            |                                 |
| MRS             | Methicillin-Resistant Staphylococcus aureus Screen, 2 Challenge      | X   |  | X   | Х                            |                                 |
| MRS5            | Methicillin-Resistant Staphylococcus aureus Screen, 5 Challenge      | Х   |  | X   | Х                            |                                 |
| MRS5M           | MRSA Screen, Molecular, 5 Challenge                                  |   |  | Х   | Х                            |                                 |
| NAT             | Nucleic Acid Testing   | Х   |  |   |                              |                                 |
| RMC             | Routine Microbiology Combination                                     | Х   |  | Χ   | Х                            |                                 |
| RML5            | Rapid Malaria 5 Challenge  | Х   |  |   |                              |                                 |
| SCP             | Stem Cell Processing   |   |  | Χ   | Х                            |                                 |
| SP1             | Norovirus  |   | Х  |   |                              |                                 |
| VBDM            | Vector-Borne Disease—Molecular                                       |   | Х  |   |                              |                                 |
| VR1             | Virology Culture   | Х   |  | Х   | Х                            |                                 |
| VRE             | Vancomycin-Resistant Enterococcus                                    | Х   |  |   |                              |                                 |
| VS              | Vaginitis Screen Antigen Detection                                   | X   |  | Х   | Х                            |                                 |

Some programs require multiple permits. If the lab is not culturing the programs in column marked "PHAC License: HPTR (RG2) if culturing," they would return the provided permit request letter signed "No Permit Required." Surveys requiring a permit under the Health of Animals Act and its Regulations (HAA/HAR) from CFIA must be accompanied by one of the following documents to demonstrate their facility meets the necessary biocontainment and biosafety requirements: a valid compliance letter issued by CFIA or a valid Pathogen and Toxin License issued by PHAC.

#### **Definitions**

HAA/HAR—Health of Animals Act and Health of Animals Regulations


HPTR—Human Pathogens and Toxins Regulations

PPA/PPR—Plant Protection Act and Plant Protection Regulations

OBCS—Office of Biohazard Containment and Safety

RG2—Risk Group 2

# During your inspection, if it's not documented, it's not compliant.



CLIA and your accreditor's standards haven't changed: You need to have complete and accurate records at inspection or you'll receive a deficiency. The CAP's Competency Assessment Hub offers tools to satisfy regulatory record-keeping requirements and meet your staff's CE needs.

#### The 2025 Competency Assessment Hub subscription includes:

- Hundreds of prewritten questions to customize assessments
- Tools and resources to build assessment and training records
- Auto-assignment of competency activities so you never miss an assessment
- Reporting tools to ensure your staff meet deadlines
- 67 CE courses in 11 laboratory disciplines

Improve your laboratory's readiness for inspection.
Add the appropriate
Competency Assessment Hub subscription to your order.

#### **Learn More**



## **Shipping Information**

#### **Shipping Terms and Conditions**

- Incoterms for all shipments are made CPT (Carriage Paid To) destination. Customers are responsible for all customs fees, duties, taxes, carrier disbursement fees, and brokerage fees. The shipping and handling fee does not cover additional costs incurred by the recipient's government or brokerage company.
- The CAP is not liable for loss or damage caused by force majeure.
- For PT/EQA orders allow up to 10 business days for international shipments via air service. Domestic orders are shipped via expedited service types such as next-day or two-day air services.

#### Shipping and Handling Fees and Customer Importation Information

Our goal is to ensure program materials are shipped to maintain stability and reach your laboratory using a reliable transportation carrier. The CAP requires the addition of a 1.25% fuel surcharge for 2025 program shipments for all continental US customers due to the increase in shipping rates. Additional shipping fees for programs shipped to all noncontinental US customers are indicated in the table below.

| Shipping and Handling Fees                                       |                                  |  |
|--|----------------------------------|--|
| Destination  | Shipping Fee Per Program (US \$) |  |
| Alaska   | \$55                             |  |
| American Samoa   | \$55                             |  |
| Canada   | \$125                            |  |
| Guam   | \$55                             |  |
| Hawaii   | \$55                             |  |
| Puerto Rico  | \$95                             |  |
| Virgin Islands   | \$95                             |  |
| Shipments beyond the continental US and destinations noted above | \$180                            |  |

Shipping and handling fees shown above are collected for shipments sent beyond the continental US and cover shipping costs and handling requirements. Additional fees, duties, carrier disbursement fees, and taxes not reflected in the CAP list price may be imposed on PT/EQA orders. Participants should contact their local customs office and local carrier's office regarding any additional charges that may be imposed.

- Discuss your local delivery requirements with your carrier and local customs authorities.
- Identify your broker with your local carrier's office.
- Some customers, including those in Mexico and Canada, are required by their governmental authorities to identify a broker to their carrier. If the customer fails to identify their brokerage partner, shipments may be delayed or re-routed in transit. Shipments for customers in Mexico who do not identify their broker to their carrier will have to reach out to TALMA, a bonded warehouse under the jurisdiction of Mexican customs authorities, to release their shipment(s). Customers in Canada will need to reach out to their carrier.
- Consider establishing an account with the local carrier for direct billing of duties and taxes. It is common practice for carriers to charge additional disbursement fees for advancing duties and taxes due to your government. If an account is not established with your local carrier's office, deliveries may be delayed or arrive Collect on Delivery (COD).
- · Inquire whether signing a power of attorney for brokerage services will expedite clearance of your shipments.
- Inquire whether there are documents you can prepare in advance and place on file for the program year.
- Local duties and tax charges may apply to shipments within your geographic area.
- Duties and import taxes imposed by countries outside of the US are the responsibility of the customer and cannot be waived by the CAP.
- Other government fees imposed by your country are the responsibility of the customer and cannot be waived by the CAP.
- · Shipments are processed CPT Destination.

| Program Code  | Program Name  |
|---|---|
| APAPCPT, APAPJPT, APAPKPT, APAPLPT, APAPMPT, PPTENR, Series 1 and 2 | Glass Slide Gynecologic Cytopathology PT Program With Glass Slide PAP Education, additional pathologist or cytotechnologist |
| APAPCE, APAPJE, APAPKE, APAPLE, APAPME, Series 1 and 2              | Cytopathology Glass Slide Education Program, additional pathologist or cytotechnologist                                     |
| AUP   | Autopsy Pathology   |
| AUP1  | Autopsy Pathology, additional pathologist   |
| BCPV  | Blood Cell Identification, Virtual  |
| BMD   | Bone Marrow Cell Differential   |
| CAPBIND*  | CAP Survey Binder   |
| CPIP/CPIP1  | Clinical Pathology Improvement Program  |
| CY  | CAP/ACMG Cytogenetics   |
| СҮНІ  | CAP/ACMG ERBB2 (HER2) Amplification by FISH, Interpretation Only  |
| DPATH/DPATH1  | Online Digital Slide Program in Dermatopathology  |
| EHE1  | Expanded Virtual Peripheral Blood Smear   |
| EMB   | Embryology  |
| FL5   | Flow Cytometry, Interpretation Only   |
| FL6   | Post-Immunotherapy Analysis   |
| FNA/FNA1  | Online Digital Slide Program in Fine-Needle Aspiration  |
| FNAG1   | Fine-Needle Aspiration Glass Slide Education Program, additional pathologist or cytotechnologist                            |
| FR/FR1  | Forensic Pathology  |
| HERI  | HER2 and ER Immunohistochemistry Interpretation Only  |
| HPATH/HPATH1  | Hematopathology Online Education  |
| NEO   | Neoplastic Cellularity  |
| NGC1  | Nongynecologic Cytopathology Education, additional pathologist or cytotechnologist  |
| NGSB1   | Next-Generation Sequencing Solid Tumor Bioinformatics   |
| NGSB3   | NGS Hematologic Malignancies Bioinformatics   |
| NGSB4   | Next-Generation Sequencing Solid Tumor Bioinformatics Hybrid  |
| NGSB5   | Next-Generation Sequencing Hematologic Malignancies Bioinformatics Hybrid   |
| NGSE  | NGS Undiagnosed Disorders—Exome   |
| NGSET   | Next-Generation Sequencing Undiagnosed Disorders—Trio Analysis  |
| NMBA/NMB1   | Navigating Multimodality Biomarkers   |
| NP/NP1  | Neuropathology Program  |
| PIP1  | Performance Improvement Program in Surgical Pathology, additional pathologist   |
| PIPW/PIPW1  | Online Performance Improvement Program in Surgical Pathology  |
| QT programs   | Quality Management Tools  |
| SEC   | CAP/ACMG DNA Sequencing Interpretation  |

<sup>\*</sup>The CAP does not charge shipping and handling for binders that are included with your order. The purchase of additional binders will incur a shipping and handling fee.

| Programs Exempt From Shipping and Handling Charges continued |   |  |
|--|---|--|
| SMCD, SM1CD, SM2CD   | MCD, SM1CD, SM2CD Semen Analysis—Online   |  |
| TICP/TICP1   | Nongynecologic Cytopathology—Intraoperative Touch Imprint/Crush Preparation Program |  |
| VBF  | Virtual Body Fluid  |  |
| VBP/VBP1   | Online Virtual Biopsy Program   |  |
| VGS1   | Virtual Gram Stain Basic Competency   |  |
| VGS2   | Virtual Gram Stain Advanced Competency  |  |
| VPBS   | Virtual Peripheral Blood Smear  |  |
| VS2  | Vaginitis Screen, Virtual Gram Stain  |  |

#### **Carriers**

The CAP will send all standard PT program shipments via the CAP's preferred carrier. If your organization is specifically requesting shipment via a freight forwarder or another designated carrier, provide the CAP with your final shipment address, account number, and the freight forwarder's US domestic address and contact information.

#### **Carrier Contact**

Carriers or customs officials may attempt to contact your PT shipping contact if there are issues regarding clearing your shipment; make sure you provide the CAP with your PT shipping contact email and local number. Please respond to these requests for additional information as soon as possible. Contact the CAP if you need additional information to expedite clearance.

If you fail to respond to information requests from carriers and customs officials, the following may occur:

- Your organization may incur additional charges for storage and management fees.
- You may incur additional fees due to disposal or return of your shipment.

#### **Special Requirements**

Discuss any special shipping requirements or updates with the CAP Customer Contact Center staff.

Communicate all requests for special shipping arrangements to the CAP a minimum of six weeks prior to the stated program ship date.

#### Deferments

Shipping dates will be determined by the CAP. The CAP will coordinate shipments with packagers, carriers, and distributors to minimize time in transit. The CAP may adjust program ship dates impacted by local holidays. When feasible, arrangements for adjustment of ship dates shall be made six weeks or more prior to the ship date. Ship dates will be adjusted to the extent material stability allows. Participants will be notified when program ship dates require adjustments.

#### **Commercial Invoice**

Commercial invoices are affixed to packages as required by international shipping conventions. The commercial invoice is an official transaction record between an exporter and an importer. Customs officials use this form to clear your shipment.

The invoice total listed on the commercial invoice is not an amount due to the CAP or your country. The invoice total is listed for the purpose of computing duties and taxes.

#### Delivery

CAP programs are shipped door-to-door service whenever possible. In instances where your country does not allow delivery to your door, the CAP can only arrange shipment to an airport. In these instances you will be notified when a program has been cleared and is ready for pickup. You must pick up your shipment at that point. If you refuse to pick up your shipment, your order for any remaining shipments may be canceled.

#### Stability

Some programs with limited stability may not be available in certain countries. For more information, contact the CAP Customer Contact Center.

| Programs With Stability Between 3 and 10 Days |   |  |
|---|---|--|
| Program Code                                  | Program Name  |  |
| B27   | HLA-B27 Typing  |  |
| EP0   | Erythropoietin  |  |
| GH2, GH5                                      | Hemoglobin A1c  |  |
| HFC   | Hemocytometer Fluid Count   |  |
| KET   | Ketones   |  |
| LN15  | 5 Hemoglobin A1c Calibration Verification/Linearity   |  |
| MXC   | HLA Crossmatching, Antibody Screen, and Identification (Class I and II)                             |  |
| MXEP  | HLA Crossmatching, Antibody Screen, and Antibody Identification (Class I/Class II),<br>Extra Plasma |  |

For CAP-accredited laboratories outside the US, the CAP requests that your laboratory perform testing on these materials. If unacceptable results are achieved and it is established that such results are due to shipping conditions, your laboratory may review options with the CAP Laboratory Accreditation Program at accred@cap.org.

| Programs With 2 Days or Less Stability |   |  |
|--|---|--|
| Program Code                           | Program Name  |  |
| BALL                                   | B-Cell Acute Lymphocytic Leukemia   |  |
| CBT                                    | Cord Blood Testing  |  |
| FL3                                    | Flow Cytometry, Immunophenotypic Characterization of Leukemia/Lymphoma                |  |
| FL8                                    | Flow Cytometry, Mature B-Cell Leukemia/Lymphoma Measurable (Minimal) Residual Disease |  |
| FL9                                    | Flow Cytometry, Plasma Cell Myeloma Measurable (Minimal) Residual Disease             |  |
| PCNEO                                  | Flow Cytometry, Plasma Cell Neoplasms   |  |
| RFAV1                                  | Rare Flow Antigen Validation, CD1a  |  |
| RFAV3                                  | Rare Flow Antigen Validation, CD30  |  |
| SCP                                    | Stem Cell Processing  |  |
| ZAP70                                  | ZAP-70 Analysis by Flow Cytometry   |  |

These programs have stability of two days or less. The CAP cannot guarantee performance or offer credits for orders placed for shipment outside of the US and Canada.

**Note:** The CAP strives to deliver all program materials in a stable condition. Programs that must be kept cold will ship with frozen cold packs or dry ice as needed and allowed by country importation regulations. If transportation to your location cannot meet these conditions, please note that replacements will not be available.

#### Dry Ice

Some shipments are packed on dry ice to maintain stability. Dry ice shipments are shipped as UN1845 dangerous goods shipments. Due to sublimation, there may not be any dry ice present when you open your kit. This condition is not an indication that the program material has been compromised. If your country does not allow dry ice shipments, your program material will be packaged with cool packs that may not be as effective in maintaining a cool environment. When you receive your shipment, follow the kit storage instructions immediately to avoid compromising the program material.

| Program Code         Program Name           ABGIC         Accuracy-Based Lipids           ABB         Accuracy-Based Testosterone, Estradiol           ABTH         Harmonized Thyroid           ABU         Accuracy-Based Urine           ABVD         Accuracy-Based Vitamin D           ACA         Antichromatin Antibody           AFD         Antifungal Drugs Monitoring           AG*         1,5-Anhydroglucitol           ARP         Antiribosomal P Antibody           BDPVS         Bacterial Detection in Platelets, Rapid           BGL, BGL1, BGL2, BGL4         CAP/ACMG Biochemical Genetics           BMV2*         Bone Specific Alkaline Phosphatase           BNP5         B-type Natriuretic Peptides           C1*, C3*/C3X*, C4*, C2*/CZX*, CZZX*/CZVM*, Z*         Chemistry and Threapeutic Drug Monitoring           C7*         Pseudocholinesterase           CMSP         CAP/ACMG Cardiomyopathy Sequencing Panel           CNVST         Copy Number Variant Solid Tumor           CRTQ         Quality Cross Check—Cardiac Markers           CRTQ         Quality Cross Check—Cardiac Markers           CS         CAP/ADLM Immunosuppressive Drugs           CY3*         Quality Cross Check—Chemistry/Therapeutic Drug Monitoring           DAI <t< th=""><th colspan="4">Program Materials Shipped on Dry Ice</th></t<> | Program Materials Shipped on Dry Ice          |  |  |  |
|--|---|--|--|--|
| ABL Accuracy-Based Lipids ABS Accuracy-Based Testosterone, Estradiol ABTH Harmonized Thyroid ABU Accuracy-Based Vitamin D ACA Antichromatin Antibody AFD Antifungal Drugs Monitoring AG* 1,5-Anhydroglucitol ARP Antiribosomal P Antibody BDPV5 Bacterial Detection in Platelets, Rapid BGL, BGL1, BGL2, BGL4 CAP/ACMG Biochemical Genetics BMV2* Bone Specific Alkaline Phosphatase BNP5 B-type Natriuretic Peptides C1*, C3*/C3X*, C4*, CZ*/CZX*, CZ2X*/CZVM*, Z* Chemistry and Therapeutic Drug Monitoring C7* Pseudocholinesterase CMSP CAP/ACMG Cardiomyopathy Sequencing Panel CNVST Copy Number Variant Solid Tumor CRT, CRTI Cardiac Markers CRTQ Quality Cross Check—Cardiac Markers CS CAP/ADLM Immunosuppressive Drugs CYS* Cystatin C CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV Everolimus FT* Fructosamine FTC Forensic Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HCRT, HCRTI High-Sensitivity Cardiac Markers   | Program Code                                  | Program Name   |  |  |
| ABS Accuracy-Based Testosterone, Estradiol ABTH Harmonized Thyroid ABU Accuracy-Based Urine ABVD Accuracy-Based Urine ABVD Accuracy-Based Urine ACA Antichromatin Antibody AFD Antifungal Drugs Monitoring AG* 1,5-Anhydroglucitol ARP Antiribosomal P Antibody BDPV5 Bacterial Detection in Platelets, Rapid BGL, BGL2, BGL4 CAP/ACMG Biochemical Genetics BMV2* Bone Specific Alkaline Phosphatase BNP5 B-type Natriuretic Peptides C1*, C3*/C3X*, C4*, C2*/C2X*, C22X*/C2VM*, Z* Chemistry and Therapeutic Drug Monitoring C7* Pseudocholinesterase CMSP CAP/ACMG Cardiomyopathy Sequencing Panel CNVST Copy Number Variant Solid Tumor CRT, CRTI Cardiac Markers CRTQ Quality Cross Check—Cardiac Markers CSC CAP/ADLM Immunosuppressive Drugs CYS* Cystatin C CZO* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV Everolimus FT* Fructosamine FTC Forensic Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HCRT, HCRTI High-Sensitivity Cardiac Markers  | ABGIC   | Accuracy-Based Glucose, Insulin, and C-peptide                     |  |  |
| ABTH ABU Accuracy-Based Urine ABVD Accuracy-Based Urine ACA Antichromatin Antibody AFD Antifungal Drugs Monitoring AG* 1,5-Anhydroglucitol ARP Antiribosomal P Antibody BDPV5 Bacterial Detection in Platelets, Rapid BGL, BGL1, BGL2, BGL4 CAP/ACMG Biochemical Genetics BMV2* Bones Pactrical Expetides C1*, C3*/C3X*, C4*, CZ*/CZX*, CZZX*/CZVM*, Z* Chemistry and Therapeutic Drug Monitoring C7* Pseudocholinesterase CMSP CAP/ACMG Cardiomyopathy Sequencing Panel CNVST Copy Number Variant Solid Tumor CRT, CRTI Cardiac Markers CRTQ Quality Cross Check—Cardiac Markers CSC CAP/ADLM Immunosuppressive Drugs CY8* Cystatin C CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV FT* Fructosamine FTC Forenis Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HCRT, HCRTI High-Sensitivity Cardiac Markers  | ABL   | Accuracy-Based Lipids  |  |  |
| ABU Accuracy-Based Urine  ABVD Accuracy-Based Vitamin D  ACA Antichromatin Antibody  AFD Antifungal Drugs Monitoring  AG* 1,5-Anhydroglucitol  ARP Antiribosomal P Antibody  BDPV5 Bacterial Detection in Platelets, Rapid  BGL, BGL1, BGL2, BGL4 CAP/ACMG Biochemical Genetics  BMV2* Bone Specific Alkaline Phosphatase  BNP5 B-type Natriuretic Peptides  C1*, C3*/C3X*, C4*, CZ2X*/CZX*/CZVM*, Z* Chemistry and Therapeutic Drug Monitoring  C7* Pseudocholinesterase  CMSP CAP/ACMG Cardiomyopathy Sequencing Panel  CNVST Copy Number Variant Solid Tumor  CRT, CRTI Cardiac Markers  CS CAP/ADLM Immunosuppressive Drugs  CYS* Cystain C  CQQ* Quality Cross Check—Cardiac Markers  CSC  CAP/ADLM Immunosuppressive Drug Monitoring  DAI Urine Drug Adulterant/Integrity  DMPM Drug Monitoring for Pain Management  EPO Erythropoietin  EV Everolimus  FT* Fructosamine  FTC Forensic Toxicology, Criminalistics  GSA* Glycated Serum Albumin  HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRQ Quality Cross Check Cardiac Markers  Glycated Serum Albumin  HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin   | ABS   | Accuracy-Based Testosterone, Estradiol                             |  |  |
| ABVD Accuracy-Based Vitamin D ACA Antichromatin Antibody AFD Antifungal Drugs Monitoring AG* 1,5-Anhydroglucitol ARP Antiribosomal P Antibody BDPV5 Bacterial Detection in Platelets, Rapid BGL, BGL2, BGL4 CAP/ACMG Biochemical Genetics BMV2* Bone Specific Alkaline Phosphatase BNP5 B-type Natriuretic Peptides C1*, C3*/C3X*, C4*, CZ*/CZX*, CZZX*/CZVM*, Z* Chemistry and Therapeutic Drug Monitoring C7* Pseudocholinesterase CMSP CAP/ACMG Cardiomyopathy Sequencing Panel CNVST Copy Number Variant Solid Tumor CRT, CRTI Cardiac Markers CRTQ Quality Cross Check—Cardiac Markers CS CAP/ADLM Immunosuppressive Drugs CYS* Cystain C CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV Everolimus FT* Fructosamine FTC Forensic Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HCRT, HCRTI High-Sensitivity Cardiac Markers  | ABTH  | Harmonized Thyroid   |  |  |
| ACA Antichromatin Antibody AFD Antifungal Drugs Monitoring AG* 1,5-Anhydroglucitol ARP Antiribosomal P Antibody BDPV5 Bacterial Detection in Platelets, Rapid BGL, BGL1, BGL2, BGL4 CAP/ACMG Biochemical Genetics BMV2* Bone Specific Alkaline Phosphatase BNP5 B-type Natriuretic Peptides C1*, C3*/C3X*, C4*, CZ*/CZX*, CZZX*/CZVM*, Z* Chemistry and Therapeutic Drug Monitoring C7* Pseudocholinesterase CMSP CAP/ACMG Cardiomyopathy Sequencing Panel CNVST Copy Number Variant Solid Tumor CRT, CRTI Cardiac Markers CRTQ Quality Cross Check—Cardiac Markers CS CAP/ADLM Immunosuppressive Drugs CYS* Cystatin C CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV Everolimus FT* Fructosamine FTC Forensic Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HCRT, HCRTI High-Sensitivity Cardiac Markers   | ABU   | Accuracy-Based Urine   |  |  |
| AFD Antifungal Drugs Monitoring AG* 1,5-Anhydroglucitol ARP Antiribosomal P Antibody BDPV5 Bacterial Detection in Platelets, Rapid BGL, BGL1, BGL2, BGL4 CAP/ACMG Biochemical Genetics BMV2* Bone Specific Alkaline Phosphatase BNP5 B-type Natriuretic Peptides C1*, C3*/C3X*, C4*, C2*/CZX*, CZ2X*/CZVM*, Z* Chemistry and Therapeutic Drug Monitoring C7* Pseudocholinesterase CMSP CAP/ACMG Cardiomyopathy Sequencing Panel CNVST COPY Number Variant Solid Tumor CRT, CRTI Cardiac Markers CS CAP/ADLM Immunosuppressive Drugs CYS* Cystatin C CZQ* Quality Cross Check—Cardiac Markers CXQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV FT* Fructosamine FTC Forensic Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HCRQ, High-Sensitivity Cardiac Markers   | ABVD  | Accuracy-Based Vitamin D   |  |  |
| AG* 1,5-Anhydroglucitol ARP Antiribosomal P Antibody BDPV5 Bacterial Detection in Platelets, Rapid BGL, BGL1, BGL2, BGL4 CAP/ACMG Biochemical Genetics BMV2* Bone Specific Alkaline Phosphatase BNP5 B-type Natriuretic Peptides C1*, C3*/C3X*, C4*, CZ*/CZX*, CZ2X*/CZVM*, Z* Chemistry and Therapeutic Drug Monitoring C7* Pseudocholinesterase CMSP CAP/ACMG Cardiomyopathy Sequencing Panel CNVST Copy Number Variant Solid Tumor CRT, CRTI Cardiac Markers CRTQ Quality Cross Check—Cardiac Markers CS CAP/ADLM Immunosuppressive Drugs CYS* Cystatin C CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV Everolimus FT* Fructosamine FTC Forensic Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Cardiac Markers  | ACA   | Antichromatin Antibody   |  |  |
| ARP Antiribosomal P Antibody  BDPV5 Bacterial Detection in Platelets, Rapid  BGL, BGL1, BGL2, BGL4 CAP/ACMG Biochemical Genetics  BMV2* Bone Specific Alkaline Phosphatase  BNP5 B-type Natriuretic Peptides  C1*, C3*/C3X*, C4*, CZ*/CZX*, CZ2X*/CZVM*, Z* Chemistry and Therapeutic Drug Monitoring  C7* Pseudocholinesterase  CMSP CAP/ACMG Cardiomyopathy Sequencing Panel  CNVST Copy Number Variant Solid Tumor  CRT, CRTI Cardiac Markers  CRTQ Quality Cross Check—Cardiac Markers  CS CAP/ADLM Immunosuppressive Drugs  CYS* Cystatin C  CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring  DAI Urine Drug Adulterant/Integrity  DMPM Drug Monitoring for Pain Management  EPO Erythropoietin  EV Everolimus  FT* Fructosamine  FTC Forensic Toxicology, Criminalistics  GSA* Glycated Serum Albumin  HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin   | AFD   | Antifungal Drugs Monitoring  |  |  |
| BDPV5       Bacterial Detection in Platelets, Rapid         BGL, BGL1, BGL2, BGL4       CAP/ACMG Biochemical Genetics         BMV2*       Bone Specific Alkaline Phosphatase         BNP5       B-type Natriuretic Peptides         C1*, C3*/C3X*, C4*, CZ*/CZX*, CZ2X*/CZVM*, Z*       Chemistry and Therapeutic Drug Monitoring         C7*       Pseudocholinesterase         CMSP       CAP/ACMG Cardiomyopathy Sequencing Panel         CNVST       Copy Number Variant Solid Tumor         CRTQ       Quality Cross Check—Cardiac Markers         CRTQ       Quality Cross Check—Cardiac Markers         CS       CAP/ADLM Immunosuppressive Drugs         CYS*       Cystatin C         CZQ*       Quality Cross Check—Chemistry/Therapeutic Drug Monitoring         DAI       Urine Drug Adulterant/Integrity         DMPM       Drug Monitoring for Pain Management         EPO       Erythropoietin         EV       Everolimus         FT*       Fructosamine         FTC       Forensic Toxicology, Criminalistics         GSA*       Glycated Serum Albumin         HCRQ       Quality Cross Check Cardiac Markers With High-Sensitivity Troponin         HCRT, HCRTI       High-Sensitivity Cardiac Markers  | AG*   | 1,5-Anhydroglucitol  |  |  |
| BGL, BGL1, BGL2, BGL4  BMV2*  Bone Specific Alkaline Phosphatase  BNP5  B-type Natriuretic Peptides  C1*, C3*/C3X*, C4*, CZ*/CZX*, CZ2X*/CZVM*, Z*  Chemistry and Therapeutic Drug Monitoring  C7*  Pseudocholinesterase  CMSP  CAP/ACMG Cardiomyopathy Sequencing Panel  CNVST  Copy Number Variant Solid Tumor  CRT, CRTI  Cardiac Markers  CS  CAP/ADLM Immunosuppressive Drugs  CYS*  Cystatin C  CZQ*  Quality Cross Check—Chemistry/Therapeutic Drug Monitoring  DAI  Urine Drug Adulterant/Integrity  DMPM  Drug Monitoring for Pain Management  EPO  Erythropoietin  EV  Everolimus  FT*  Fructosamine  FTC  GSA*  Glycated Serum Albumin  HCRQ  Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRQ  Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HGRT, HCRTI  High-Sensitivity Cardiac Markers   | ARP   | Antiribosomal P Antibody   |  |  |
| BMV2* Bone Specific Alkaline Phosphatase BNP5 B-type Natriuretic Peptides C1*, C3*/C3X*, C4*, CZ*/CZX*, CZ2X*/CZVM*, Z* Chemistry and Therapeutic Drug Monitoring C7* Pseudocholinesterase CMSP CAP/ACMG Cardiomyopathy Sequencing Panel CNVST Copy Number Variant Solid Tumor CRT, CRTI Cardiac Markers CRTQ Quality Cross Check—Cardiac Markers CS CAP/ADLM Immunosuppressive Drugs CYS* Cystatin C CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV Everolimus FT* Fructosamine FTC GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HCRT, HCRTI High-Sensitivity Cardiac Markers   | BDPV5   | Bacterial Detection in Platelets, Rapid                            |  |  |
| B-type Natriuretic Peptides  C1*, C3*/C3X*, C4*, CZ*/CZX*, CZ2X*/CZVM*, Z*  Chemistry and Therapeutic Drug Monitoring  C7*  Pseudocholinesterase  CMSP  CAP/ACMG Cardiomyopathy Sequencing Panel  CNVST  Copy Number Variant Solid Tumor  CRT, CRTI  Cardiac Markers  CRTQ  Quality Cross Check—Cardiac Markers  CS  CAP/ADLM Immunosuppressive Drugs  CYS*  Cystatin C  CZQ*  Quality Cross Check—Chemistry/Therapeutic Drug Monitoring  DAI  Urine Drug Adulterant/Integrity  DMPM  Drug Monitoring for Pain Management  EPO  Erythropoietin  EV  Everolimus  FT*  Fructosamine  FTC  Forensic Toxicology, Criminalistics  GSA*  Glycated Serum Albumin  HCRQ  Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRQ  Quality Cross Check Cardiac Markers   | BGL, BGL1, BGL2, BGL4                         | CAP/ACMG Biochemical Genetics                                      |  |  |
| C1*, C3*/C3X*, C4*, CZ*/CZX*, CZ2X*/CZVM*, Z*  Chemistry and Therapeutic Drug Monitoring  C7*  Pseudocholinesterase  CMSP  CAP/ACMG Cardiomyopathy Sequencing Panel  CNVST  Copy Number Variant Solid Tumor  CRT, CRTI  Cardiac Markers  CRTQ  Quality Cross Check—Cardiac Markers  CS  CAP/ADLM Immunosuppressive Drugs  CYS*  Cystatin C  CZQ*  Quality Cross Check—Chemistry/Therapeutic Drug Monitoring  DAI  Urine Drug Adulterant/Integrity  DMPM  Drug Monitoring for Pain Management  EPO  Erythropoietin  EV  Everolimus  FT*  Fructosamine  FTC  Forensic Toxicology, Criminalistics  GSA*  Glycated Serum Albumin  HCRQ  Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRT, HCRTI  High-Sensitivity Cardiac Markers  | BMV2*   | Bone Specific Alkaline Phosphatase                                 |  |  |
| C7* Pseudocholinesterase  CMSP CAP/ACMG Cardiomyopathy Sequencing Panel  CNVST Copy Number Variant Solid Tumor  CRT, CRTI Cardiac Markers  CRTQ Quality Cross Check—Cardiac Markers  CS CAP/ADLM Immunosuppressive Drugs  CYS* Cystatin C  CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring  DAI Urine Drug Adulterant/Integrity  DMPM Drug Monitoring for Pain Management  EPO Erythropoietin  EV Everolimus  FT* Fructosamine  FTC Forensic Toxicology, Criminalistics  GSA* Glycated Serum Albumin  HCRQ Quality Cross Check Cardiac Markers  High-Sensitivity Cardiac Markers  | BNP5  | B-type Natriuretic Peptides  |  |  |
| CMSP CAP/ACMG Cardiomyopathy Sequencing Panel CNVST Copy Number Variant Solid Tumor CRT, CRTI Cardiac Markers CRTQ Quality Cross Check—Cardiac Markers CS CAP/ADLM Immunosuppressive Drugs CYS* Cystatin C CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV Everolimus FT* Fructosamine FTC Forensic Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HCRT, HCRTI High-Sensitivity Cardiac Markers  | C1*, C3*/C3X*, C4*, CZ*/CZX*, CZ2X*/CZVM*, Z* | Chemistry and Therapeutic Drug Monitoring                          |  |  |
| CNVST CRT, CRTI Cardiac Markers CRTQ Quality Cross Check—Cardiac Markers CS CAP/ADLM Immunosuppressive Drugs CYS* Cystatin C CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV Everolimus FT* Fructosamine FTC Forensic Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRT, HCRTI High-Sensitivity Cardiac Markers  | C7*   | Pseudocholinesterase   |  |  |
| CRT, CRTI CRTQ Quality Cross Check—Cardiac Markers CS CAP/ADLM Immunosuppressive Drugs CYS* Cystatin C CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV Everolimus FT* Fructosamine FTC Forensic Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HGRT, HCRTI High-Sensitivity Cardiac Markers  | CMSP  | CAP/ACMG Cardiomyopathy Sequencing Panel                           |  |  |
| CRTQ Quality Cross Check—Cardiac Markers CS CAP/ADLM Immunosuppressive Drugs CYS* Cystatin C CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV Everolimus FT* Fructosamine FTC Forensic Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HCRT, HCRTI High-Sensitivity Cardiac Markers  | CNVST   | Copy Number Variant Solid Tumor                                    |  |  |
| CS CAP/ADLM Immunosuppressive Drugs CYS* Cystatin C CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV Everolimus FT* Fructosamine FTC Forensic Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HCRT, HCRTI High-Sensitivity Cardiac Markers   | CRT, CRTI                                     | Cardiac Markers  |  |  |
| CYS* Cystatin C CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity  DMPM Drug Monitoring for Pain Management EPO Erythropoietin EV Everolimus FT* Fructosamine FTC Forensic Toxicology, Criminalistics GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HCRT, HCRTI High-Sensitivity Cardiac Markers  | CRTQ  | Quality Cross Check—Cardiac Markers                                |  |  |
| CZQ* Quality Cross Check—Chemistry/Therapeutic Drug Monitoring DAI Urine Drug Adulterant/Integrity  DMPM Drug Monitoring for Pain Management  EPO Erythropoietin  EV Everolimus  FT* Fructosamine  FTC Forensic Toxicology, Criminalistics  GSA* Glycated Serum Albumin  HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRT, HCRTI High-Sensitivity Cardiac Markers   | CS  | CAP/ADLM Immunosuppressive Drugs                                   |  |  |
| DAI Urine Drug Adulterant/Integrity  DMPM Drug Monitoring for Pain Management  EPO Erythropoietin  EV Everolimus  FT* Fructosamine  FTC Forensic Toxicology, Criminalistics  GSA* Glycated Serum Albumin  HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRT, HCRTI High-Sensitivity Cardiac Markers  | CYS*  | Cystatin C   |  |  |
| DMPM Drug Monitoring for Pain Management  EPO Erythropoietin  EV Everolimus  FT* Fructosamine  FTC Forensic Toxicology, Criminalistics  GSA* Glycated Serum Albumin  HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRT, HCRTI High-Sensitivity Cardiac Markers   | CZQ*  | Quality Cross Check—Chemistry/Therapeutic Drug Monitoring          |  |  |
| EPO Erythropoietin  EV Everolimus  FT* Fructosamine  FTC Forensic Toxicology, Criminalistics  GSA* Glycated Serum Albumin  HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRT, HCRTI High-Sensitivity Cardiac Markers   | DAI   | Urine Drug Adulterant/Integrity                                    |  |  |
| EV Everolimus  FT* Fructosamine  FTC Forensic Toxicology, Criminalistics  GSA* Glycated Serum Albumin  HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRT, HCRTI High-Sensitivity Cardiac Markers   | DMPM  | Drug Monitoring for Pain Management                                |  |  |
| FT* Fructosamine  FTC Forensic Toxicology, Criminalistics  GSA* Glycated Serum Albumin  HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRT, HCRTI High-Sensitivity Cardiac Markers  | EPO EPO                                       | Erythropoietin   |  |  |
| FTC Forensic Toxicology, Criminalistics  GSA* Glycated Serum Albumin  HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRT, HCRTI High-Sensitivity Cardiac Markers  | EV  | Everolimus   |  |  |
| GSA* Glycated Serum Albumin  HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin  HCRT, HCRTI High-Sensitivity Cardiac Markers   | FT*   | Fructosamine   |  |  |
| GSA* Glycated Serum Albumin HCRQ Quality Cross Check Cardiac Markers With High-Sensitivity Troponin HCRT, HCRTI High-Sensitivity Cardiac Markers   | FTC   | Forensic Toxicology, Criminalistics                                |  |  |
| HCRT, HCRTI High-Sensitivity Cardiac Markers   | GSA*  | Glycated Serum Albumin   |  |  |
| · · · · · · · · · · · · · · · · · · ·  | HCRQ  | Quality Cross Check Cardiac Markers With High-Sensitivity Troponin |  |  |
| HCV2 Hepatitis C Viral Load  | HCRT, HCRTI                                   | High-Sensitivity Cardiac Markers                                   |  |  |
|  | HCV2  | Hepatitis C Viral Load   |  |  |

<sup>\*</sup>This program ships with a cool pack to laboratories in the US, Puerto Rico, Guam, Virgin Islands, and American Samoa.

| Program Code          | Program Name   |
|-----------------------|--|
| HIVG                  | HIV Genotyping   |
| HV2                   | HIV Viral Load   |
| ICSP                  | CAP/ACMG Inherited Cancer Sequencing Panel                     |
| IFS*                  | Interfering Substances   |
| IGHV                  | IGHV Mutation Analysis   |
| K*, KK*, KVM*         | Ligand Assay—General   |
| KET                   | Ketones  |
| LN2*, LN2BV*          | Chemistry Calibration Verification/Linearity                   |
| LN24                  | Creatinine Accuracy Calibration Verification/Linearity         |
| LN25                  | Troponin Calibration Verification/Linearity                    |
| LN30                  | B-type Natriuretic Peptides Calibration Verification/Linearity |
| LN31                  | Immunosuppressive Drugs Calibration Verification/Linearity     |
| LN35, LN36, LN37      | Coagulation Calibration Verification/Linearity                 |
| LN41                  | Procalcitonin Calibration Verification/Linearity               |
| LN44                  | Fibrinogen Calibration Verification/Linearity                  |
| LN45                  | HCV Viral Load Calibration Verification/Linearity              |
| LN46                  | C-peptide/Insulin Calibration Verification/Linearity           |
| LN47                  | High-Sensitivity Troponin T Calibration Verification/Linearity |
| LN48                  | High-Sensitivity Troponin I Calibration Verification/Linearity |
| LN49*                 | Cystatin C Calibration Verification/Linearity                  |
| LN50                  | Thyroid Calibration Verification Linearity                     |
| LN51                  | Factor VIII Calibration Verification Linearity                 |
| LN52                  | HBV Calibration Verification Linerarity                        |
| LN5*, LN5S*           | Ligand Calibration Verification/Linearity                      |
| LPE*                  | Lipoprotein Electrophoresis                                    |
| MHO, MHO1, MHO2, MHO3 | Molecular Hematologic Oncology                                 |
| MPA                   | Mycophenolic Acid  |
| MRD, MRD1, MRD2       | Measurable (Minimal) Residual Disease                          |
| NAT                   | Nucleic Acid Testing   |
| NB*, NB2*             | Neonatal Bilirubin   |
| NOB                   | Novel Opioids and Benzodiazepines                              |
| N                     | Urine Chemistry, Special                                       |
| NTA                   | Nicotine and Tobacco Alkaloids                                 |
| OFD                   | Oral Fluid for Drugs of Abuse                                  |
| RAP*                  | Renin and Aldosterone  |
| RNA                   | Fusion RNA Sequencing  |
| SALC                  | Salivary Cortisol  |
| SARC                  | Sarcoma Fusion Gene  |

<sup>\*</sup>This program ships with a cool pack to laboratories in the US, Puerto Rico, Guam, Virgin Islands, and American Samoa.


| Program Materials Shipped on Dry Ice continued |   |  |
|--|---|--|
| Program Code                                   | Program Name                                    |  |
| SCDD   | Synthetic Cannabinoid/Designer Drugs            |  |
| SCO  | Serum Carryover                                 |  |
| Т  | Toxicology                                      |  |
| TBLA   | Total Bile Acids                                |  |
| THCB   | Blood Cannabinoids                              |  |
| TM*,TMX*                                       | Tumor Markers                                   |  |
| TMB  | Tumor Mutational Burden                         |  |
| UDS  | CAP/ADLM Urine Drug Testing, Screening          |  |
| UDS6   | CAP/ADLM Urine Drug Testing, Screening, Limited |  |
| UDSM   | Urine Drug Testing, Screen, Validated Material  |  |
| UPBG   | Porphobilinogen, Urine                          |  |
| UT   | Urine Toxicology                                |  |
| UTCO   | Urine Toxicology Carryover                      |  |
| VF   | Vitreous Fluid, Postmortem                      |  |
| VITD*  | 25-OH Vitamin D, Total                          |  |
| Y*, YY*, YVM*                                  | Sex Hormones                                    |  |
| ZE   | Therapeutic Drug Monitoring—Extended            |  |

<sup>\*</sup>This program ships with a cool pack to laboratories in the US, Puerto Rico, Guam, Virgin Islands, and American Samoa.

#### Options for Customers Outside the US

If you are ordering programs shipped with dry ice or cool packs and the average temperature in your country is higher than 25°C (77°F), the CAP recommends you upgrade your shipment packaging to the extended shipper (XDS). The XDS is a dual insulation shipper intended to maintain the cold chain to destinations with warmer climates. The fee associated with this service is \$30 per program. Contact our Customer Contact Center at contactcenter@cap.org or +1-847-832-7000, Option 1 to upgrade to the XDS.

# With direct transmission, less equals more.



Transmit your quantitative PT/EQA results directly to the CAP with direct transmission. Your laboratory will spend less time manually entering results, which will free up resources for other priorities. Plus, you will reduce clerical errors and streamline your process to be more like patient testing.

Get connected. Learn more at cap.org

Less complicated

More accurate

Less time entering results

More time for patient testing

